BRIEF published on 05/17/2024 at 09:52, 6 months 4 days ago Elis: Monthly updating of capital and voting rights Share Capital Voting Rights Investors April 2024 Elis
PRESS RELEASE published on 05/17/2024 at 09:47, 6 months 4 days ago Elis: Disclosure of the number of shares forming the capital and of the total number of voting rights as of 30 04 2024 Disclosure of the number of shares forming the capital and of the total number of voting rights as of 30 April 2024 by Elis SA. Details available on Elis website Voting Rights Shares Investor Relations Disclosure Elis SA
Published on 11/21/2024 at 13:30, 18 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 18 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 48 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 48 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 48 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 13 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 33 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 50 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 28 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 3 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 3 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
